Use of the Internet is becoming widespread throughout the world. Its use in
the domain of drug safety and pharmacovigilance is spreading rapidly. Gove
rnments and industry have taken the lead in developing extensive web sites.
The US Food and Drug Administration (FDA), the European Agency for the Eva
luation of Medicinal Products (EMEA) and other agencies have developed site
s containing enormous amounts of information both on pharmacovigilance in g
eneral and on specific drugs in particular. Under the US 'Freedom of Inform
ation Act' the FDA has put major parts of its adverse event database on lin
e. Regulatory documents are also available from the FDA site or from hyperl
inks described in the site. The US Center for Drug Evaluation and Research
updates its site most days and maintains a free automated e-mail announceme
nt service of these updates. Similarly, the EMEA updates its site frequentl
y and publishes extensive material including regulatory documents, guidelin
es, European Public Assessment Reports on newly approved medications and ot
her useful information. A free update service by e-mail is also available.
Although English is the primary language used on the EMEA site, some of the
information is available in other languages.
Pharmaceutical companies are not using the Internet for pharmacovigilance y
et. Rather, the Internet is being used for promotion of their products and
for informing consumers on general information on diseases, for financial a
nd investor data and for employment opportunities, etc. Other organisations
such as lobbies, consumer groups and medical journals are also beginning t
o use the Internet.
The electronic transmission of safety information, using the standards deve
loped by the International Conference on Harmonization, is currently being
tested for the transmission of individual patient adverse event information
between companies and governments. In addition, the FDA has begun to accep
t adverse events from healthcare providers and consumers directly on line u
sing an electronic version of its MedWatch form. It is expected that these
developments will change the nature of the way pharmacovigilance is carried
out.
Significant issues will arise from this including privacy concerns. The Eu
ropean Union's 1995 directive on 'the protection of individuals with regard
to the processing of personal data and on the free movement of such data (
95/46/EC)' went into effect in October 1998. The enabling legislation now b
eing passed by the member states will produce significant changes in the wa
y companies and governments handle individual patient data in order to assu
re the privacy and protection of individuals.